Novel Therapies for Advanced Squamous Cell Carcinoma of the Lung
- 1 February 2016
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 12 (5) , 659-667
Abstract
Advanced squamous non-small-cell lung carcinoma (SqCC) has traditionally been considered the ‘neglected sibling’ compared with lung adenocarcinoma due to lack of effective targeted treatment options. Currently, limited progress has been made in the systemic treatment of advanced disease and combination chemotherapy remains the gold standard. However, the recent completion of the molecular characterization of SqCC revealed an interestingly complex genomic profile, comprising various genetic alterations that can potentially function as molecular targets for the development of novel targeted agents. Recent encouraging results of the use of immune checkpoint inhibitors in several neoplasms has emerged as a promising novel treatment option for advanced SqCC. Future personalized studies, enrolling SqCC patients according to specific driving mutations are underway.Keywords
This publication has 48 references indexed in Scilit:
- Nedaplatin: a cisplatin derivative in cancer chemotherapyCancer Management and Research, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancerBMC Cancer, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyThe Lancet Oncology, 2012
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 MutationsClinical Cancer Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005